Tysabri Re-Entry Hinges On Effective Risk Management: Diagnostics May Be Key
Executive Summary
Any risk management program tied to the market re-entry of Biogen Idec/Elan's Tysabri would likely include diagnostic procedures to test for early signs of progressive multifocal leukoencephalopathy
You may also be interested in...
Tysabri Registry Monthly Reports And Patient Checklist Follow-Up Advised
Biogen Idec should receive monthly reports from its Tysabri risk management patient registry on checklists filled out prior to infusion, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee recommended March 8
Tysabri Registry Monthly Reports And Patient Checklist Follow-Up Advised
Biogen Idec should receive monthly reports from its Tysabri risk management patient registry on checklists filled out prior to infusion, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee recommended March 8
Tysabri Resubmission: Early Safety Test For New Commissioner
The potential market re-entry for the multiple sclerosis therapy Tysabri (natalizumab) is likely to be one of the most high-profile safety issues facing the FDA under new leadership over the next six months